Open access · CC-BY
via OpenAlex
Amelioration of pathologic α-synuclein-induced Parkinson’s disease by irisin
Tae‐In Kam, Hyejin Park, Shih-Ching Chou, Jonathan G. Van Vranken, Melanie J. Mittenbühler, Hyeonwoo Kim, Mu A, Yu Ree Choi, Devanik Biswas, Justin L. Wang, Yu Jung Shin, Alexis K Loder, Senthilkumar S. Karuppagounder, Christiane D. Wrann, Valina Lynn Dawson
Proceedings of the National Academy of Sciences · 2022 · ▲ 137 citations
Abstract
Physical activity provides clinical benefit in Parkinson's disease (PD). Irisin is an exercise-induced polypeptide secreted by skeletal muscle that crosses the blood-brain barrier and mediates certain effects of exercise. Here, we show that irisin prevents pathologic α-synuclein (α-syn)-induced neurodegeneration in the α-syn preformed fibril (PFF) mouse model of sporadic PD. Intravenous delivery of irisin via viral vectors following the stereotaxic intrastriatal injection of α-syn PFF cause a reduction in the formation of pathologic α-syn and prevented the loss of dopamine neurons and lowering of striatal dopamine. Irisin also substantially reduced the α-syn PFF-induced motor deficits as assessed behaviorally by the pole and grip strength test. Recombinant sustained irisin treatment of primary cortical neurons attenuated α-syn PFF toxicity by reducing the formation of phosphorylated serine 129 of α-syn and neuronal cell death. Tandem mass spectrometry and biochemical analysis revealed that irisin reduced pathologic α-syn by enhancing endolysosomal degradation of pathologic α-syn. Our findings highlight the potential for therapeutic disease modification of irisin in PD.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1073/pnas.2204835119
- Canonical
- link ↗
- Fetched
- 2026-11-13 MST
Cite this
APA
Kam, T., Park, H., Chou, S., Vranken, J.G.V., Mittenbühler, M.J., Kim, H., A, M., Choi, Y.R., Biswas, D., Wang, J.L., Shin, Y.J., Loder, A.K., Karuppagounder, S.S., Wrann, C.D., Dawson, V.L., Spiegelman, B.M., & Dawson, T.M. (2022). Amelioration of pathologic α-synuclein-induced Parkinson’s disease by irisin. <em>Proceedings of the National Academy of Sciences</em>. https://doi.org/10.1073/pnas.2204835119
Vancouver
Kam T, Park H, Chou S, Vranken JGV, Mittenbühler MJ, Kim H, et al. Amelioration of pathologic α-synuclein-induced Parkinson’s disease by irisin. Proceedings of the National Academy of Sciences. 2022. doi:10.1073/pnas.2204835119.
BibTeX
@article{taein2022Amelio,
title = {Amelioration of pathologic α-synuclein-induced Parkinson’s disease by irisin},
author = {Tae‐In Kam and Hyejin Park and Shih-Ching Chou and Jonathan G. Van Vranken and Melanie J. Mittenbühler and Hyeonwoo Kim and Mu A and Yu Ree Choi and Devanik Biswas and Justin L. Wang and Yu Jung Shin and Alexis K Loder and Senthilkumar S. Karuppagounder and Christiane D. Wrann and Valina Lynn Dawson and Bruce M. Spiegelman and Ted M. Dawson},
journal = {Proceedings of the National Academy of Sciences},
year = {2022},
doi = {10.1073/pnas.2204835119},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Neurobiology of Disease 2014
Preprint · CC-BY
Loss of dopamine disrupts circadian rhythms in a mouse model of Parkinson's disease
Molecular biology reports 2026
Citation only
The interplay between chronobiology, neuroinflammation, and the glymphatic system in neurodegenerative diseases.
Neuron 2019
Open access · OA
Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson’s Disease
PLoS ONE 2025
Open access · CC-BY
Circadian rhythm disruption as a potential contributor to BPPV: Evidence from a young rat model vestibular effects of circadian disruption
Frontiers in Neuroscience 2020
Open access · CC-BY
LRRK2 Kinase Inhibition Rescues Deficits in Lysosome Function Due to Heterozygous GBA1 Expression in Human iPSC-Derived Neurons
Molecular Neurodegeneration 2023
Open access · CC-BY